Survodutide Research for Obesity
An evidence-based overview of research examining Survodutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 dose-finding RCT (N=387) demonstrated dose-dependent weight loss, reaching 14.9% at 46 weeks with the 4.8mg dose vs 2.8% with placebo. The phase 3 SYNCHRONIZE-1 trial (N=725, 76 weeks) was published in June 2026: on the treatment-regimen estimand, which the paper names as the primary analysis, body weight fell 12.2% at 3.6 mg and 13.0% at 6.0 mg against 5.4% with placebo, and 72.6% and 71.9% of participants reached at least 5% weight reduction against 46.3%.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.